OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance
Yasheng Zhu, Xiuquan Ye, Hao Shen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14633-14652
Closed Access | Times Cited: 7
Yasheng Zhu, Xiuquan Ye, Hao Shen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14633-14652
Closed Access | Times Cited: 7
Showing 7 citing articles:
Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers
Jingya Zhang, Pengxing He, Wenwen Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Jingya Zhang, Pengxing He, Wenwen Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations
Peng He, Haiyan Li, Zhenyu Yang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117323-117323
Closed Access
Peng He, Haiyan Li, Zhenyu Yang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117323-117323
Closed Access
Rational Design of a Potent, Selective, and Metabolically Stable CDK9 Inhibitor to Counteract Osimertinib Resistance through Mcl-1 Suppression and Enhanced BRD4 Co-Targeting
Ti-Zhi Wu, Jiali Huang, Xiankang Zhang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Ti-Zhi Wu, Jiali Huang, Xiankang Zhang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance
Jiadai Liu, Wenyan Nie, Haoran Nie, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107313-107313
Closed Access | Times Cited: 3
Jiadai Liu, Wenyan Nie, Haoran Nie, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107313-107313
Closed Access | Times Cited: 3
Perspectives on current approaches to virtual screening in drug discovery
Ingo Muegge, Jörg Bentzien, Ge Yunhui
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 10, pp. 1173-1183
Closed Access | Times Cited: 2
Ingo Muegge, Jörg Bentzien, Ge Yunhui
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 10, pp. 1173-1183
Closed Access | Times Cited: 2
From Challenges to Solutions: A Review of Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Overcome the C797S Triple Mutation in Non-Small Cell Lung Cancer
Iqrar Ahmad, Harun Patel
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117178-117178
Closed Access | Times Cited: 1
Iqrar Ahmad, Harun Patel
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117178-117178
Closed Access | Times Cited: 1
Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies
Yang Zhou, J.S. Kang, Xiaoyun Lu
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14702-14722
Closed Access
Yang Zhou, J.S. Kang, Xiaoyun Lu
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14702-14722
Closed Access
